Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Audit of Veterinary Drug Retail Sales in Russia (September and Q1 – Q3 2020)

Monday, October 19, 2020

Between January and September 2020, the stagnating sales of veterinary drugs in the retail market amounted to RUB 15.97 bln (retail prices, VAT included), which is in monetary terms (rubles) 0.3% lower than in 2019. The volume in physical terms is 144.4 bln minimum dosage units (MDU), which is 0.3% higher than in 2019.

Temperature anomalies strongly influenced the consumption trends in the spring; in fact, the heat came a month earlier than usual, which led to an earlier surge in demand for seasonal medicines. At the same time, this fall has also brought a surprise; September turned out to be almost summer warm in most parts of Russia. The weather affected the consumption trends once again; the demand for certain drug groups increased significantly. In particular, the following groups showed record-worthy dynamics in physical terms at the end of September 2020: anthelmintics (excluding combined drugs), immunosuppressive agents (mainly antipruritic Apoquel), cardiotonics, antispasmodics, NSAIDs, as well as certain groups of antibacterials (semi-synthetic penicillin+beta-lactamase inhibitor, tetracycline and others). Interestingly, that did not lead to a significant increase in sales volume in monetary terms at the end of the month, with the dynamics of +23.3% in physical and -1.4% in monetary terms.

It was mostly the sales of drugs in the lower price segment that were growing since consumers had clearly switched to cheaper products in a number of groups. In particular, the demand dropped significantly for combined anthelmintic drugs: Milbemax by Elanco, Prazicid by Apicenna and others, and increased for mono-drugs: Alben and Fascocide by Agrovetzashchita.

GiGi (Latvia) and Vetoquinol (France) have the highest dynamics among the top 15 foreign manufacturers with the largest sales volume for the period between January and September 2020. Cardiotonic for dogs PimoPet and anthelmintic MilbePet contributed to the former company’s dynamics of +40%. Drug for kidney failure Ipakitine and combined drug for otodectosis Oridermyl contributed to the dynamics of Vetoquinol (+34%).

As for Russian manufacturers, Scientific and Production Company Research Center (sales grown by 3 times, with Vetom contributing to the dynamics) and Agrobioprom (+45%) have the highest dynamics in the top 15. The sales of Agrobioprom’s Pchelodar line products contributed to the dynamics the most, with insectoacaricide Pchelodar Binakar, cardiovascular drug Pchelodar Zookard and hepatoprotector Pchelodar Hepatolux being the most demanded products.

Volume of the Russian retail market of veterinary drugs in monetary (consumer prices, VAT included) and physical (MDU) terms (2019, Q1 – Q3 2020)

Share: